To provide all patients with matching hematopoietic stem cell products international collaboration is essential. WMDA strives that userfriendly tools are available to find the best stem cell source without unnecessary administrative burden. This can be achieved by centralised collection of information, modern ICT environment, centralised approach for adverse events reporting and transparent regulatory requirements.